Syndax has also tested the drug in AML driven by mutations to the NPM1 gene. The company is planning a first half 2025 regulatory submission seeking to expand the drug’s approval to AML driven ...
Ziftomenib, Kura's most advanced drug candidate, targets AML with NPM1 mutations, showing promising Phase 1b and a ...
Risk categorization of AML based on karyotyping of leukemic blasts has become routine. Mutations in NPM1, CCAAT enhancer-binding protein-α (with double-mutations) and FCT3-internal tandem ...
1monon MSN
Other analyses of Black patients found that mutations in NPM1 and NRAS genes were associated with inferior disease-free ...
Secondary-type Mutations in NPM1-mutated AML-MRC With a History of MDS or MDS/MPN Do secondary mutations explain why patients with AML with a history of myelodysplasia-related changes and the NPM1 ...
The U.S. FDA also granted Fast Track designation to revumenib for the treatment of adult and pediatric patients with R/R acute leukemias harboring a KMT2A rearrangement or NPM1 mutation and ...
The U.S. FDA also granted Fast Track designation to revumenib for the treatment of adult and pediatric patients with R/R acute leukemias harboring a KMT2A rearrangement or NPM1 mutation and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback